U.S. reaches deal to reopen shuttered baby formula plant

WASHINGTON

U.S. officials have reached an agreement with Abbott to allow it to restart its largest domestic plant. However, new products will not be shipped from the site for two months.

According to the agreement, Abbott will work with outside specialists to raise its standards and reduce the bacterial contamination at Sturgis, Michigan facility. The Food and Drug Administration is investigating the matter since early this year. A federal judge must approve the deal. It is a legally binding agreement between Abbott and FDA on the steps required to reopen the factory.

The U.S. Department of Justice filed this agreement in court for the FDA.

Abbott will resume production once again. saidNew products will not be available in stores until eight to ten week after they are made. The FDA must approve the company’s timeline for restarting manufacturing.

Monday night, the FDA will announce additional measures to allow foreign imports to the United States to solve the supply problem. This comes at a time when President Joe Biden is under intense pressure to do more in order to alleviate the shortage that has left many families searching online for formula or food banks.

The FDA started investigating four bacterial infections in infants who ingested powdered formula made from Abbott’s plant in January. Two babies died.

The company stopped production in February and recalled several brands powdered formula. This was to squeeze supplies that were already tightened due to supply chain disruptions and stockpiling of COVID-19. Walgreen’s, CVS and Walgreen’s have imposed limits on the number of containers customers can buy each visit because of this shortage.

The outrage has quickly exploded and given Republicans a new talking point to use against Biden in advance of the November midterm elections.

Abbott is one the four largest U.S. producers of formula and its brands account almost half of that market.

After a six week inspection, FDA investigators published in March a list of issues, which included lax safety and sanitation standards, as well as a history of bacterial infection in many parts of the facility.

Abbott, a Chicago-based company, has stressed that its products are not directly related to the bacterial infections in children. Federal investigators found that the bacteria samples from its plant were not compatible with the ones taken from the babies. In the meantime, FDA has not yet made a decision. The company repeatedly stated that it is ready for manufacturing to resume.

Former FDA officials stated that fixing the problems found at Abbott’s plant is a slow process. Infant formula facilities are subject to greater scrutiny than other food facilities. It is essential for companies to thoroughly clean their facility and equipment, retrain employees, and repeatedly test and document that there is no contamination.

Robert Califf, FDA Commissioner, stated Monday to ABC News that an announcement regarding imports of baby formula from outside the United States was coming soon. He said that it is crucial to make sure the formula instructions are understood by mothers and caregivers.

Baby formulas from Europe and Canada are equivalent in quality to the ones made in America, according to pediatricians. However, 98% domestically produced infant formula is the norm. There are many hurdles for companies looking to enter the U.S., including strict FDA manufacturing standards and rigorous research.

Steven Hyde, a San Diego father, has struggled to find formula for his daughter with medical issues. She was using an Abbott formula and had to change due to the recalls and subsequent shortages.

Zoie Hyde was 19 months old when she was born without any kidneys. This rare condition is life-threatening and requires dialysis, feeding tubes until she is able to eat enough to receive a transplant.

Hyde saidBefore customs and costs made it difficult, he had been using an organic brand imported from overseas. Friends and strangers from other states have sent Davis different brands. However, each brand requires additional blood tests and monitoring. said.

Davis said that Zoie has overcome many obstacles and is now walking, talking, learning, and doing well on other developmental milestones. said.

He said, “She’s a shining star in my life,” said.

Lindsay Tanner, AP Medical writer, contributed to this article from Chicago.